Related Experiment Video

Updated: May 31, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Renovascular and renoprotective properties of telmisartan: clinical utility

Marco Ladino1, Ivonne Hernandez Schulman

  • 1Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA. ischulman@med.miami.edu

International Journal of Nephrology and Renovascular Disease
|June 23, 2011
PubMed

Insights

Chronic kidney disease (CKD) impacts millions, with hypertension and diabetes as primary causes. Telmisartan, an angiotensin receptor blocker, offers renal and vascular protection beyond blood pressure control.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) affects 26 million US adults, with type 2 diabetes and hypertension as leading causes.
  • Progression to end-stage renal disease occurs despite adequate blood pressure control in many CKD patients.
  • Angiotensin receptor blockers (ARBs) are crucial for managing hypertension and CKD, offering renoprotective benefits independent of blood pressure reduction.

Purpose of the Study:

  • To review the renal and vascular protective effects of telmisartan.
  • To highlight telmisartan's pharmacological properties beyond angiotensin II type 1 receptor blockade.

Main Methods:

  • Literature review of studies on telmisartan's effects in CKD and hypertension.
  • Analysis of telmisartan's mechanism of action, including PPAR-γ activation.

Main Results:

  • Telmisartan demonstrates renoprotective effects in CKD patients.
  • Telmisartan exhibits vascular protective properties.
  • Pharmacological actions include PPAR-γ activation, contributing to its benefits.

Conclusions:

  • Telmisartan offers significant renal and vascular protection in CKD management.
  • Its unique properties, including PPAR-γ activation, provide benefits beyond standard ARB function.
  • Telmisartan is a valuable therapeutic option for patients with hypertension and CKD.

Keywords:
PPAR-γangiotensin II receptorhypertensionkidney diseasesvascular diseases

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...